Edition:
United Kingdom

China Biologic Products Holdings Inc (CBPO.OQ)

CBPO.OQ on NASDAQ Stock Exchange Global Select Market

91.99USD
17 Aug 2018
Change (% chg)

$1.59 (+1.76%)
Prev Close
$90.40
Open
$90.21
Day's High
$92.77
Day's Low
$89.50
Volume
65,938
Avg. Vol
128,699
52-wk High
$107.32
52-wk Low
$71.87

Latest Key Developments (Source: Significant Developments)

China Biologic Products Q2 Earnings Per Share $0.83
Friday, 3 Aug 2018 

Aug 3 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2018.Q2 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.17.Q2 EARNINGS PER SHARE $0.83.Q2 SALES ROSE 34.8 PERCENT TO $120.4 MILLION.SAYS REVISES FULL YEAR FINANCIAL FORECAST.IS MAKING A DOWNWARD REVISION TO ITS FULL YEAR 2018 FORECAST.EXPECTS FY2018 NON-GAAP ADJUSTED INCOME FROM OPERATIONS TO INCREASE BY 0% TO 2% IN RMB TERMS.CHINA BIOLOGIC PRODUCTS-"Q2 CONTINUED TO BE CHALLENGING DUE TO ONGOING IMPACT OF REGULATORY CHANGES & INTENSIFIED COMPETITION IN CHINA'S HEALTHCARE MARKET".SEES FY2018 NON-GAAP ADJUSTED NET INCOME TO DECREASE BY 2% TO 4% IN RMB TERMS.CHINA BIOLOGIC-2018 FORECAST WAS LOWERED TO ACCOUNT FOR WORSE-THAN-EXPECTED RESULTS FOR H1 2018 AND ONGOING CHALLENGING OUTLOOK IN H2 OF YEAR.CHINA BIOLOGIC PRODUCTS HOLDINGS-FOR H2, EXPECT "REGULATORY HEADWINDS AND MARKET COMPETITIVE DYNAMICS TO PERSIST", WHICH WILL IMPACT GUIDANCE FOR YEAR.  Full Article

China Biologic Says Excluding Financial Results Of Tianxinfu, Q1 Sales To Grow About 2% In RMB
Tuesday, 24 Apr 2018 

April 24 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC PRODUCTS HOLDINGS - EXCLUDING FINANCIAL RESULTS OF TIANXINFU, TOTAL SALES IN Q1 OF 2018 EXPECTED TO GROW ABOUT 2% IN RMB TERMS.CHINA BIOLOGIC PRODUCTS - INCLUDING TIANXINFU'S CONTRIBUTION, TOTAL SALES FOR Q1 2018 IS EXPECTED TO GROW APPROXIMATELY 13% IN RMB TERMS.CHINA BIOLOGIC PRODUCTS HOLDINGS- EXCLUDING TIANXINFU RESULTS, Q1 NON-GAAP ADJUSTED NET INCOME EXPECTED TO DECLINE 12-14% Y-O-Y IN RMB TERMS.CHINA BIOLOGIC - INCLUDING TIANXINFU'S CONTRIBUTION, NON-GAAP ADJUSTED. NET INCOME FOR Q1 2018 IS EXPECTED TO GROW 1% TO 3% YEAR OVER YEAR IN RMB TERMS.CHINA BIOLOGIC - ONGOING REFORM HEADWINDS INITIATED IN 2017 IN CHINA'S HEALTHCARE MARKET FURTHER NEGATIVELY IMPACTED Q1 SALES REVENUE, PROFIT GROWTH.  Full Article

China Biologic Sees FY 2017 Sales Up About 10.5 Pct
Monday, 8 Jan 2018 

Jan 8 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC ANNOUNCES CORPORATE UPDATE.SEES FY 2017 SALES UP ABOUT 10.5 PERCENT.  Full Article

China Biologic posts Q3 adj. earnings per share $1.38
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - China Biologic Products Holdings Inc :China Biologic reports unaudited financial results for the third quarter of 2017.Q3 adjusted non-GAAP earnings per share $1.38.Q3 earnings per share $1.11.Q3 sales rose 15.1 percent to $99.6 million.China Biologic Products Holdings Inc - ‍reiterates full year non-GAAP adjusted net income forecast​.China Biologic Products Holdings - ‍adjusting FY 2017 forecast of total sales growth to 9 pct-10 pct in RMB terms compared to previous estimates of 13 pct-15 pct​.  Full Article

China Biologic agrees to acquire Tianxinfu from PWM
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - China Biologic Products Holdings Inc :China Biologic agrees to acquire Tianxinfu from PWM.China Biologic Products Holdings Inc - ‍It has agreed to acquire 80% equity interest in Tianxinfu (Beijing) Medical Appliance Co., Ltd​.China Biologic Products - ‍In exchange for acquisition of 80% equity interest in Tianxinfu from PWM, Cbpo will issue 5.5 million ordinary shares to PWM​.China Biologic Products - ‍PWM is expected to hold approximately 16.66% of outstanding share capital of Cbpo taking into effect new issuance​ post deal.China Biologic Products - Board determined to exempt deal from causing PWM to be deemed "acquiring person" under CBPO's preferred shares rights agreement​.China Biologic Products Holdings Inc - ‍Acquire 80% equity interest in Tianxinfu from PW Medtech Group Limited​.China Biologic Products - ‍CBPO elected to be exempted from shareholder approval requirement under applicable rules of nasdaq market for proposed deal.China Biologic Products Holdings - ‍Elected to be exempted from shareholder approval requirement under applicable rules of Nasdaq stock market for deal.China Biologic Products Holdings Inc - ‍Post deal close, PWM expected to hold about 16.66% of share capital of co taking into effect new issuance​.  Full Article

China Biologic receives approval for commercial manufacturing of human fibrinogen
Monday, 9 Oct 2017 

Oct 9 (Reuters) - China Biologic Products Holdings Inc :China Biologic receives approval for commercial manufacturing of human fibrinogen.China Biologic Products Holdings Inc - ‍expects first batch of products to be released to market by end of 2017​.China Biologic Products Holdings Inc - ‍expect to see meaningful profit contribution from fibrinogen in 2018​.China Biologic Products Holdings - unit received approval from China food and drug administration for commercial manufacturing of human fibrinogen.  Full Article

Ex-Warburg Pincus China head targets up to $1.5 bln for China fund - sources

HONG KONG, June 22 Private-equity firm Centurium Capital, founded by former Warburg Pincus China head, is targeting to raise up to $1.5 billion in its China-focused fund to invest in healthcare and consumer sectors, two sources with knowledge of the matter said.